In the history of medicine, there have been a handful of moments when a single drug changed the conversation entirely. Penicillin. The polio vaccine. Statins. Prozac.
We are living through one of those moments right now.
The drug is semaglutide, sold under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight loss). The class is GLP-1 receptor agonists. And the story of how a diabetes medication became the most culturally significant drug of the 21st century — triggering shortages, transforming body image conversations, reshaping entire industries, and generating over $20 billion in annual revenue — is one of the most remarkable in modern medicine.
What Is a GLP-1 Drug?
GLP-1 stands for glucagon-like peptide-1 — a hormone your body naturally produces in the gut after you eat. It does several things:
- Signals the pancreas to release insulin (lowering blood sugar)
- Suppresses glucagon (a hormone that raises blood sugar)
- Slows gastric emptying (food leaves your stomach more slowly)
- Sends signals to the brain that reduce hunger and increase feelings of fullness
That last point is why GLP-1 drugs became a weight loss phenomenon. They don't just reduce appetite — they fundamentally alter the brain's reward signalling around food. Many patients report that food simply stops being interesting. The obsessive thoughts about eating that many overweight people experience — what researchers call "food noise" — largely disappear.
Semaglutide is a synthetic version of GLP-1 that has been engineered to last much longer in the body than the natural hormone. A natural GLP-1 molecule breaks down in minutes. Semaglutide, injected once a week, stays active for days.
The Weight Loss Numbers Are Unlike Anything Before
For context, the weight loss pharmaceutical industry before GLP-1 drugs was a graveyard of failed promises. Most drugs delivered modest results (5–8% body weight loss), came with serious side effects, or both. Fen-phen caused heart valve damage. Meridia was withdrawn over cardiovascular risks. The bar was low and the failures were frequent.
Then came the clinical trial data for semaglutide:
STEP 1 trial (2021): Adults with obesity given weekly semaglutide lost an average of 14.9% of their body weight over 68 weeks. The placebo group lost 2.4%.
SURMOUNT-1 trial for tirzepatide (Eli Lilly's Mounjaro/Zepbound): Average weight loss of 20.9% — almost a quarter of body weight.
These are numbers the field had never seen. To appreciate the magnitude: a 15–20% reduction in body weight is enough to:
- Resolve type 2 diabetes in many patients
- Significantly reduce blood pressure and cholesterol
- Reduce the need for knee replacement surgery (less load on joints)
- Improve sleep apnoea
- Reduce liver fat (non-alcoholic fatty liver disease)
And then came the SELECT trial in 2023 — a cardiovascular outcomes study of 17,604 patients. Semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity who had established cardiovascular disease, but no diabetes.
This changed the conversation permanently. Ozempic was no longer just a weight loss drug. It was a cardiovascular drug, a metabolic drug, potentially a longevity drug.
What the Research Is Now Showing Beyond Weight Loss
The clinical evidence for GLP-1 effects beyond weight loss has expanded rapidly:
Kidney disease: The FLOW trial (2024) showed semaglutide reduced the progression of chronic kidney disease by 24% in patients with type 2 diabetes and kidney impairment. The trial was stopped early because the results were so clear.
Alcohol and addiction: Multiple studies and a flood of anecdotal reports suggest GLP-1 drugs reduce alcohol consumption, sometimes dramatically. The prevailing theory: the drugs dampen the reward signalling system in the brain, and alcohol's reward signals use some of the same pathways as food. Clinical trials for alcohol use disorder are now underway.
Alzheimer's disease: Observational studies have found associations between GLP-1 drug use and reduced rates of Alzheimer's diagnosis. The mechanism is unclear — it may be related to reduced inflammation, improved insulin signalling in the brain, or direct neurological effects. Trials are ongoing.
Depression: GLP-1 receptors exist in the brain regions associated with mood regulation. Early data suggests GLP-1 drugs may have antidepressant effects independent of weight loss. Again — trials are ongoing.
The picture emerging is of a drug class that may be operating on fundamental biological systems related to inflammation, metabolism, and brain reward — with effects that extend far beyond the gut.
The Side Effects Nobody Talks About Enough
The enthusiasm around GLP-1 drugs is real and largely justified. But the conversation often glosses over meaningful concerns.
Nausea and GI symptoms
The most common side effects are nausea, vomiting, diarrhoea, and constipation — particularly when starting the drug or increasing the dose. For most patients these are manageable and improve over time. For some, they are severe enough to discontinue.
Muscle loss
This is the most underappreciated risk. When people lose significant weight quickly, a substantial portion of the loss is lean muscle mass, not just fat. Studies suggest 25–40% of weight lost on GLP-1 drugs may be muscle. This is concerning because muscle mass is strongly associated with long-term metabolic health, mobility, and longevity. Experts now strongly recommend combining GLP-1 treatment with resistance training and high protein intake to preserve muscle.
The rebound problem
When patients stop taking GLP-1 drugs, the majority regain most of the weight they lost — typically within one to two years. This raises a profound question: are these drugs a lifelong treatment, like statins for cholesterol? If so, at $800–$1,200/month (before insurance), the affordability implications are enormous.
Rare but serious risks
- Pancreatitis — inflammation of the pancreas. Rare, but patients with a history of pancreatitis are generally advised to avoid these drugs.
- Gastroparesis — severely delayed stomach emptying. There have been reports of patients developing this condition, causing long-term digestive problems.
- Thyroid tumours — seen in rodent studies. Not confirmed in humans, but patients with personal or family history of certain thyroid cancers are excluded from treatment.
- Sarcopenic obesity — losing muscle while retaining fat (particularly in older adults who don't exercise). This can leave people lighter but actually less metabolically healthy.
The Business Disruption Is Massive
The GLP-1 wave has created one of the most significant business disruptions in consumer history — affecting industries that had nothing to do with pharmaceuticals.
Food and beverage: If millions of people are experiencing reduced appetite and less "food noise," they eat less. Snack companies reported sales declines. McDonald's noted lower average order sizes in markets with high GLP-1 adoption. Analysts now routinely model "GLP-1 impact" into food sector forecasts.
Bariatric surgery: Weight loss surgery volumes have declined meaningfully in markets where GLP-1 drugs are widely available. Surgical centres have had to pivot.
Clothing and retail: Apparel brands are seeing shifts in sizing demand. Plus-size clothing demand has decreased in some markets. Retailers are adjusting their inventory models.
Cardiovascular devices: If GLP-1 drugs prevent heart attacks at scale, demand for stents, pacemakers, and cardiac procedures will eventually decline.
Novo Nordisk and Eli Lilly: The two companies that dominate GLP-1 supply (Novo with semaglutide, Eli Lilly with tirzepatide/Mounjaro) have become among the most valuable pharmaceutical companies in history. Novo Nordisk briefly surpassed the entire GDP of Denmark — the country where it is headquartered.
Access and Affordability: The Equity Problem
Here is where the story becomes uncomfortable.
In the United States, Wegovy costs approximately $1,300/month without insurance. Most US insurance plans covered it inconsistently; Medicare was initially prohibited from covering weight loss drugs (this is changing, slowly). The result: GLP-1 drugs are disproportionately used by wealthy, insured patients.
In India, Bangladesh, and most of Africa, these drugs are effectively inaccessible at brand prices.
Generic versions are beginning to emerge as patents expire and compounding pharmacies fill the gap, but Novo Nordisk and Eli Lilly are fighting vigorously to protect their market positions.
The equity dimension of a potentially transformative treatment being accessible primarily to the wealthy in wealthy countries is a challenge that mirrors every major pharmaceutical innovation before it — and one that hasn't been solved yet.
Where This Is Going
The GLP-1 class is expanding rapidly:
Oral versions: Novo Nordisk has developed an oral semaglutide pill (Rybelsus). Uptake has been slower than injections, but oral delivery would dramatically expand access and convenience.
Next-generation dual and triple agonists: Eli Lilly's tirzepatide targets both GLP-1 and GIP receptors, producing greater weight loss than semaglutide alone. Drugs targeting three pathways simultaneously (GLP-1 + GIP + glucagon) are in trials, with early data suggesting 25%+ weight loss.
Retatrutide and amycretin: Early-stage candidates showing weight loss of 25–30% in Phase 2 trials. The ceiling keeps moving.
Non-obesity applications: The pipeline of trials for addiction, neurodegeneration, heart failure, and NASH (fatty liver disease) is enormous. The next decade of GLP-1 research may be as significant as the weight loss story.
The Bigger Picture
The GLP-1 story forces a rethinking of some deeply held assumptions.
For decades, obesity was treated as primarily a behavioural problem — a matter of insufficient willpower, poor choices, lack of discipline. The extraordinary effectiveness of GLP-1 drugs is strong evidence against this framing. If a weekly injection can switch off the neurological drive to overeat in a majority of patients, the "just eat less and exercise more" prescription looks increasingly like telling someone with depression to "just cheer up."
This doesn't mean lifestyle doesn't matter — the evidence for exercise, sleep, and diet quality is robust and independent of any drug. But it does mean that for many people, the biological drivers of obesity are more powerful than willpower-based interventions can overcome.
The GLP-1 revolution is, at its core, a story about what happens when medicine finally catches up to a problem that affected billions of people and was largely dismissed as a personal failing.
The drug changed. The biology didn't. And the implications — medical, economic, cultural, ethical — are still unfolding.
Interested in related topics? See our pieces on intermittent fasting and the science of eating and what the science of aging teaches us about living well now.